⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12104219 | 1.00 | — | — | |
| SCHEMBL5881822 | 0.78 | — | — | |
| SCHEMBL13024358 | 0.76 | CA1 (0.46) | — | |
| SCHEMBL27040194 | 0.76 | CA1 (0.46) | — | |
| SCHEMBL107272 | 0.72 | — | — | |
| SCHEMBL696653 | 0.69 | — | — | |
| SCHEMBL13024371 | 0.69 | CA1 (0.44) | — | |
| SCHEMBL5393533 | 0.67 | — | — | |
| SCHEMBL6126625 | 0.67 | — | — | |
| SCHEMBL1110045 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115190762-B | Novel substituted sulfonylureas Sulfonimidurea derivatives | 兹杜斯生命科学有限公司 | 2025-03-14 | — | — | CN | claimed |
| EP-4110058-A1 | NOVEL SUBSTITUTED SULFONYLUREA AND SULFOXIMINEUREA DERIVATIVES | Zydus Lifesciences Limited (IN) | 2023-01-04 | — | — | EP | claimed |
| CN-115190762-A | Novel substituted sulfonylurea and sulfonimidurea derivatives | 兹杜斯生命科学有限公司 | 2022-10-14 | — | — | CN | claimed |
| WO-2017180457-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | WO | claimed |
| EP-3204361-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica N.V. (BE) | 2017-08-16 | — | — | EP | claimed |
| WO-2016057731-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-14 | — | — | WO | claimed |
| EP-1790639-B1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2014-03-26 | — | — | EP | claimed |
| JP-2012500821-A | — | — | 2012-01-12 | — | — | JP | claimed |
| JP-2011529031-A | — | — | 2011-12-01 | — | — | JP | claimed |
| JP-4778954-B2 | — | — | 2011-09-21 | — | — | JP | claimed |
| WO-2005090315-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N. V. (BE) | 2005-09-29 | — | — | WO | claimed |
| WO-2004099210-A1 | 6-ARYLMETHYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2004-11-18 | — | — | WO | claimed |
| WO-2004099211-A1 | 6-CYCLYLMETHYL- AND 6-ALKYLMETHYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2004-11-18 | — | — | WO | claimed |
| JP-2002538151-A | — | — | 2002-11-12 | — | — | JP | claimed |
| EP-1159273-A1 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CATHEPSIN S | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000051998-A1 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CATHEPSIN S | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| EP-0912182-A4 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | MERCK & CO INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0912182-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | Merck & Co., Inc. (US) | 1999-05-06 | — | — | EP | claimed |
| WO-1998000144-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | claimed |
| CN-1036764-A | Indole derivatives and preparation method thereof and the pharmaceutical composition that contains these compounds | MADAUS & CO DR (DE) | 1989-11-01 | — | — | CN | claimed |